Perspective Therapeutics (CATX) EPS (Weighted Average and Diluted) (2023 - 2026)

Perspective Therapeutics has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.25 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.25, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.41 (down 13.71% YoY), and the FY2025 annual result was -$1.41, down 15.57% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.25 for Q1 2026 at Perspective Therapeutics, up from -$0.51 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.01 in Q1 2023 to a low of -$1.06 in Q4 2023.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.3 (2025), against an average of -$0.36.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 47.06% in 2024, while the deepest fall reached 2600.0% in 2024.
• Perspective Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.06 in 2023, then soared by 43.4% to -$0.6 in 2024, then grew by 15.0% to -$0.51 in 2025, then jumped by 50.98% to -$0.25 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.25 (Q1 2026), -$0.51 (Q4 2025), and -$0.35 (Q3 2025), per Business Quant data.